Lena Bosch, Peter-Paul M Zwetsloot, Maaike Brons, Gerardus P J van Hout, Manon G van der Meer, Mariusz K Szymanski, Anne-Marie Troost-Oppelaar, Faiz Z Ramjankhan, Pim van der Harst, Monica Gianoli, Marish I F J Oerlemans, Linda W van Laake
BACKGROUND: A left ventricular assist device (LVAD) is a life-saving but intensive therapy for patients with end-stage heart failure. We evaluated the healthcare consumption in a cohort of LVAD patients in our centre over 6 years. METHODS: All patients with a primary LVAD implantation at the University Medical Centre Utrecht in Utrecht, the Netherlands from 2016 through 2021 were included in this analysis. Subsequent hospital stay, outpatient clinic visits, emergency department visits and readmissions were recorded...
August 14, 2024: Netherlands Heart Journal